Determination of amlodipine and furosemide with newly developed and validated rp-hplc method in commercially available tablet dosage forms

Basit Öğe Kaydı
dc.authorscopusid57218906057
dc.authorscopusid14032701900
dc.authorscopusid6602229150
dc.authorscopusid57221923900
dc.contributor.authorŞimşek F.O.
dc.contributor.authorKaynak M.S.
dc.contributor.authorŞanlı N.
dc.contributor.authorŞahin S.
dc.date.accessioned2024-08-04T20:00:59Z
dc.date.available2024-08-04T20:00:59Z
dc.date.issued2012
dc.departmentİnönü Üniversitesien_US
dc.description.abstractThe aim of this study was to develop a new, fast, reliable and validated RP-HPLC method for the simultaneous determination of amlodipine and furosemide in tablet dosage forms. A C18 column (Fortis™ 250x4.60 mm 5 ?m) which was heated at 45oC during the analysis, was used for the separation and quantification of these drugs. The mobile phase consisted of water (15 mM o-phosphoric acid, pH 5.0) and acetonitrile (50:50 v/v). Analyses were run at a flow rate 1.0 mL.min-1 and UV detector was set at 238 nm. The injection volume was 20 ?L and total run time for an assay was approximately 5 min. The developed method was validated according to the ICH guideline. For the application of the proposed RP-HPLC method, commercially available four different AML containing tablets (one reference (Norvasc) and three generic (Dilapin, Monovasc, Penvasc) tablets) and commercially available two different FSM containing tablets (one reference (Lasix) and one generic (Desal) tablet) were obtained from the market and analyzed for their drug content. Under the given chromatographic conditions, AML and FSM were eluted at 4.28 and 3.68 min., respectively. The method was linear in the concentration range of 1.0 to 16.0 ?g.mL-1 and 0.1 to 12.0 ?g.mL-1 for AML and FSM, respectively with a correlation coefficient >0.999. LOD and LOQ were 0.642 ?g.mL-1 and 2.139 ?g.mL-1 for AML 0.010 ?g.mL-1 and 0.031 ?g.mL-1 for FSM, respectively. Under the conditions used, the analysis completely fulfilled the system suitability test limits suggested by FDA for the quantitative chromatographic methods. The method was successfully applied for the analysis of these drugs in commercially available tablets. © 2012, Hacettepe University, Faculty of Pharmacy. All rights reserved.en_US
dc.identifier.endpage158en_US
dc.identifier.issn1300-0608
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-85030774720en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage145en_US
dc.identifier.urihttps://hdl.handle.net/11616/91152
dc.identifier.volume32en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherHacettepe University, Faculty of Pharmacyen_US
dc.relation.ispartofHacettepe University Journal of the Faculty of Pharmacyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAmlodipineen_US
dc.subjectDrug Analysisen_US
dc.subjectFurosemideen_US
dc.subjectHPLCen_US
dc.titleDetermination of amlodipine and furosemide with newly developed and validated rp-hplc method in commercially available tablet dosage formsen_US
dc.title.alternativeAmlodipin ve furosemidin ticari tablet dozaj Şekillerinden eş zamanlı tayini İcin valide edilmiş bir rp-hplc metodun geliştirilmesien_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu